Free Trial

Olema Pharmaceuticals (OLMA) Insider Trading & Ownership

Olema Pharmaceuticals logo
$6.10 +0.31 (+5.35%)
(As of 12/20/2024 05:45 PM ET)

Olema Pharmaceuticals (NASDAQ:OLMA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
19.40%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
5
Amount Of
Insider Selling
(Last 12 Months)
$42.77 M
Get OLMA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Olema Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

OLMA Insider Buying and Selling by Quarter

Olema Pharmaceuticals Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2024G. Walmsley GrahamDirectorSell700,761$6.75$4,730,136.75  
12/10/2024Cyrus HarmonDirectorSell8,256$9.37$77,358.72  
12/10/2024David C MylesInsiderSell12,452$9.38$116,799.76  
12/10/2024Sean BohenCEOSell52,328$9.37$490,313.36  
8/1/2024Biocapital Advisors L ParadigmMajor ShareholderSell2,400,000$14.91$35,784,000.00  
7/29/2024Cyrus HarmonDirectorSell4,066$15.58$63,348.28  
7/11/2024Cyrus HarmonDirectorSell5,000$12.26$61,300.00  
6/28/2024Cyrus HarmonDirectorSell20,000$10.77$215,400.00  
6/3/2024Cyrus HarmonDirectorSell5,000$10.93$54,650.00  
5/31/2024Cyrus HarmonDirectorSell15,000$9.41$141,150.00  
5/6/2024Cyrus HarmonDirectorSell5,000$10.92$54,600.00  
4/30/2024Cyrus HarmonDirectorSell15,000$9.51$142,650.00  
3/28/2024Cyrus HarmonDirectorSell20,000$10.97$219,400.00  
2/29/2024Cyrus HarmonDirectorSell25,000$12.41$310,250.00  
1/31/2024Cyrus HarmonDirectorSell25,000$12.23$305,750.00  
(Data available from 1/1/2013 forward)

OLMA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Olema Pharmaceuticals includes Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G. Walmsley Graham, Kinney Horn, Naseem Zojwalla, and Sean Bohen. Learn more on insiders at OLMA.

19.40% of Olema Pharmaceuticals stock is owned by insiders. Learn more on OLMA's insider holdings.

The following insiders have purchased OLMA shares in the last 24 months: Biocapital Advisors L Paradigm ($1,160,000.00), Bvf Partners L P/Il ($14,818,370.88), and G. Walmsley Graham ($1,871,235.30).

Insiders have purchased a total of 1,737,802 OLMA shares in the last 24 months for a total of $17,849,606.18 bought.

The following insiders have sold OLMA shares in the last 24 months: Biocapital Advisors L Paradigm ($35,784,000.00), Cyrus Harmon ($3,061,900.12), David C Myles ($483,348.03), G. Walmsley Graham ($4,730,136.75), Naseem Zojwalla ($110,721.24), and Sean Bohen ($926,193.20).

Insiders have sold a total of 3,501,218 Olema Pharmaceuticals shares in the last 24 months for a total of $45,096,299.34 sold.

Olema Pharmaceuticals Key Executives

  • Dr. Sean P. Bohen M.D. (Age 57)
    Ph.D., President, CEO & Director
    Compensation: $1.15M
  • Mr. Shane William Charles Kovacs M.B.A. (Age 50)
    Chief Operating & Financial Officer
    Compensation: $820.37k
  • Dr. Naseem Zojwalla M.D. (Age 51)
    Chief Medical Officer
    Compensation: $753.37k
  • Ms. Julie Dexter
    Senior VP & Head of People
  • Dr. David C. Myles Ph.D. (Age 61)
    Chief Discovery & Non-Clinical Development Officer
    Compensation: $200k
  • Ms. Demiana Faltaos Ph.D.
    Pharm.D., VP & Head of Clinical Pharmacology
  • Mr. John B. Moriarty Jr. (Age 56)
    ESQ., J.D., Corporate Secretary
    Compensation: $434.32k
  • Ms. Sasha Austin CPA
    VP of Finance & Controller


This page (NASDAQ:OLMA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners